Apotex believes that every man, woman and child is entitled to affordable medical care and freedom from pain and suffering.
For close to 40 years, Apotex has met the healthcare challenges of tomorrow and fought hard to build a successful worldwide pharmaceutical company. Through a strategy of vertical integration, Apotex has built an exceptional scientific and manufacturing base that supports a global sales and marketing infrastructure. We have done this on the heels of our continued commitment to excellence.
Apotex is focused on meeting the world's need for the highest quality, affordable medicines. We have built the facilities, the scientific R&D base, and the technology to meet the healthcare needs of the world for today and tomorrow. With an established network of international affiliates and distributors, our medicines are present in more than 115 countries.
In 1974, born out of entrepreneurial efforts and strong scientific roots, and with just 2 employees, our chairman had a vision for our success and growth.
Today, that vision is now realized. Apotex is a global leader in providing affordable quality healthcare products as the largest Canadian owned pharmaceutical company.
We are committed to providing quality products through a secure global supply chain with a broad based product portfolio.
In addition we have a simple yet powerful mission... "Apotex is an independent, dynamic, Canadian pharmaceutical company committed to R&D, manufacturing and distributing a broad range of high quality, affordable medicines to patients, healthcare providers, payers and governments worldwide. We will always meet global regulatory, quality and compliance requirements. We value and respect our employees, our business partners, our suppliers, our customers and the communities we serve while operating with accountability and integrity in everything we do."
The Apotex Group of Companies occupies over 325 thousand square meters of facilities with state-of-the art technology to meet the needs of the world's healthcare systems. Apotex continues to improve on its production capabilities, and can now produce approximately 30 billion dosages per year.
We continue to invest in our future intellectual and capital infrastructures. Presently, we produce over 300 medicines in over 4000 formats and dosages, including difficult to make products such as soft gel caps and transdermal patches. Our R&D program is supported by close to 2000 scientific staff including 110 PhD's, and has well over 600 products under development, from solid dosage & bio-pharmaceuticals across all technology platforms. This is accomplished through advanced capabilities in the development of Active Pharmaceutical Ingredients (API's) and finished dosage formulations.
The innovative research arm of Apotex is ApoPharma Inc which has developed medicines such as Ferriprox for the treatment of Thalassemia. The pipeline includes iron chelators for other indications.
The Apotex Group and our facilities are recognized around the world as among the best. This has resulted in approvals by many health agencies around the world including the U.S. Food and Drug Administration, the Canadian Therapeutics Products Directorate, the European Medicines Evaluation Agency and the Australian Therapeutics Goods Administration. These approvals are the base upon which we have been able to build our International Business.
Regulatory requirements in Canada, the United States, Europe and Australia require that all generic products meet rigorous standards for bioequivalence. Testing standards used in Canada are recognized as amongst the most stringent in the world. All Apotex products meet these standards, ensuring that the fundamental cornerstone of bioequivalence to the brand reference standard is achieved.
Apotex is the number one supplier of generic pharmaceuticals in Canada, filling more than 85 million prescriptions per year - on average 1 in 5 prescriptions are filled with an Apotex product.
The world has a tremendous need for quality, affordable medicines. During the last 40 years we have built a global network in over 115 countries. This network consists of affiliates, distributors & subsidiaries in Latin America, Europe, the Middle East and Australasia.
As you can see, during our corporate history, we have built a tremendous presence in the pharmaceutical landscape, and we look forward to the next 40 years of growth, exceptional service and commitment to excellence to our customers.
In the future, we will continue to be recognized as a global leader within the pharmaceutical industry. We will maintain this position by expanding our presence in existing International markets, as well as entering new ones.
To do this we will continue to build valuable long-term sales partnerships where the customer gets what they want, when they need it. It will be built on the foundation of reliability of the supply chain, the speed of product development and hundreds of products to meet the needs of your healthcare system.
We are proud to foster an environment that is committed to excellence in all that we do. At Apotex, our innovation does not end in the lab. It just starts there.